Abstract
Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced non-small-cell lung cancer after other treatment options have failed. Despite several setbacks during the development of gefitinib, might it now be back on the path to blockbuster status?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Molecular Cancer Open Access 04 August 2022
-
Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
Protein & Cell Open Access 28 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).
Cersosimo, R. J. Lung cancer: a review. Am. J. Health Syst. Pharm. 59, 611–642 (2002).
Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for the treatment of cancer. Nature Rev. Drug Discov. 2, 325–334 (2003).
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7(S4), 2–8 (2002).
Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).
Barker, A. J. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911–1914 (2001).
FDA Drug Approvals List [online] (cited 28 May 2003) <http://www.fda.gov/cder/foi/label/2003/21399_iressa_lbl.pdf> (2003).
Wakeling, A. E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749–5754 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muhsin, M., Graham, J. & Kirkpatrick, P. Gefitinib. Nat Rev Drug Discov 2, 515–516 (2003). https://doi.org/10.1038/nrd1136
Issue Date:
DOI: https://doi.org/10.1038/nrd1136
This article is cited by
-
Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents
Medicinal Chemistry Research (2023)
-
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Molecular Cancer (2022)
-
Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
Protein & Cell (2022)
-
Rational design of multi-targeting ruthenium- and platinum-based anticancer complexes
Science China Chemistry (2016)
-
Synthesis and antitumor activity of 3-[(methyl)bis(5-trialkylsilyl-furan-2-yl)silyl]propylamines
Chemistry of Heterocyclic Compounds (2012)